Following Firdapse US Launch, Catalyst Estimates 2019 Revenues of $102M
Catalyst Pharmaceuticals expects to report 2019 net product revenues of $102 million for Firdapse (amifampridine), the first and only therapy available for treating the symptoms of Lambert-Eaton myasthenic syndrome (LEMS). In addition, the biopharmaceutical company anticipates 2020 Firdapse net product revenues of $135 million to $155…